anxiety

Goal disorientation and lack of vision
Biotech

Vistagen fails another phase 3 anxiety trial, spies path forward

With a post hoc analysis showing a nominally statistically significant improvement, the biotech plans to talk to the FDA about a path to approval.
Nick Paul Taylor Jun 30, 2026 9:48am
An arrow incrementally going up stairs before pointing straight up Blue background

Otsuka posts phase 3b ADHD trial win ahead of looming FDA ruling

Jun 25, 2026 9:13am
reducing people on team

Vistagen lays off 20% of staff to focus on anxiety candidate

Mar 12, 2026 1:16pm
kite fly sky blue sky flying

AtaiBeckley's MDMA drug improves anxiety in ph. 2 trial

Feb 26, 2026 1:32pm
dart board miss failure

Vistagen's social anxiety disorder asset stumbles in phase 3

Dec 17, 2025 2:44pm
Red arrow decreasing

Neuphoria nixes social anxiety program after phase 3 flop

Oct 21, 2025 10:44am